Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc.

Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...

And welcome to the Vertex Pharmaceuticals Third Quarter 2024 ... those regarding Vertex’s marketed medicines for cystic fibrosis, sickle cell disease and beta thalassemia, our pipeline ...

Vertex Pharmaceuticals Inc., a leading biotechnology firm, focuses on developing breakthrough therapies for serious diseases, including cystic fibrosis, sickle cell disease, and transfusion ...

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

Combing through scientific literature, Casgevy’s creators found that adults with genes that would normally produce sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT), but ...

BOSTON--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.